Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pentaglobin** is a plasma-derived, IgM-enriched polyvalent human immunoglobulin product for intravenous infusion developed by Biotest. Each mL contains 50 mg human plasma proteins, comprising approximately 38 mg IgG, 6 mg IgM, and 6 mg IgA. Its pooled polyclonal antibodies provide broad passive humoral immune support, including binding and neutralization of bacterial antigens and toxins such as lipopolysaccharide, enhancement of opsonization and pathogen clearance, and immunomodulatory effects. It is indicated in certain markets as adjunctive treatment for severe bacterial infections alongside antibiotics and as immunoglobulin replacement in immunocompromised patients with severe secondary antibody deficiency. ([ansm.sante.fr](https://ansm.sante.fr/uploads/2024/12/10/int-smpc-pentaglobin-20230926vj-clean.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pentaglobin.